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Abstract 
Transdermal delivery of hydrophilic drugs is challenging. This study presents a novel sustained 
epidermal powder delivery technology (sEPD) for safe, efficient, and sustained delivery of 
hydrophilic drugs across the skin. SEPD is based on coating powder drugs into high-aspect-
ratio, micro-coating channels (MCCs) followed by topical application of powder drug-coated 
array patches onto ablative fractional laser-generated skin MCs to deliver drugs into the skin. 
We found sEPD could efficiently deliver chemical drugs without excipients and biologics drugs 
in the presence of sugar excipients into the skin with a duration of ~12 hours. Interestingly the 
sEPD significantly improved zidovudine bioavailability by ~100% as compared to oral gavage 
delivery. SEPD of insulin was found to maintain blood glucose levels in normal range for at least 
6 hours in chemical-induced diabetes mice, while subcutaneous injection failed to maintain 
blood glucose levels in normal range. SEPD of anti-programmed death-1 antibody showed more 
potent anti-tumor efficacy than intraperitoneal injection in B16F10 melanoma models. Tiny skin 
MCs and ‘bulk’ drug powder inside relatively deep MCCs are crucial to induce the sustained 
drug release. The improved bioavailability and functionality warrants further development of the 
novel sEPD for clinical use.  
Introduction 
Oral administration remains the most popular route for drug delivery due to its convenience and 
non-invasiveness [1]. Yet, drugs delivered orally can be extensively degraded in the 
gastrointestinal tract (GI) and metabolized in the liver before reaching systemic circulation. The 
GI tract degradation and first-pass metabolism present significant challenges for oral delivery of 
certain chemical drugs and most of the biologics drugs. Transdermal delivery has been actively 
pursued for alternative drug delivery with following advantages [2]. Firstly, transdermal delivery 
bypasses first-pass metabolism and avoids the harsh environment of the GI tract, potentially 
improving drug bioavailability. Most biologics drugs are compatible for transdermal drug 
delivery. Secondly, skin has a large surface area and is readily accessible. Thirdly, transdermal 
delivery can sustain drug release and potentially reduce dosing frequency. Sustained release is 
also likely to reduce peaking plasma drug levels and drug toxicity. Lastly, transdermal delivery 
can be needle-free, painless, and self-applicable with good patient compliance. 
 
Despite these advantages, only a limited number of small hydrophobic drugs, like nicotine, 
fentanyl, and lidocaine, are approved for transdermal delivery [2,3]. This is mainly because the 
superficial Stratum Corneum (SC) layer of the skin is impermeable to most of the hydrophilic 
molecules due to its highly compacted lipid structure [4]. While the SC layer is essential to 
protect from environmental pathogen invasion, it also presents as a formidable barrier for 
transdermal drug delivery. Different methods, like hydration, chemical enhancers, tape stripping, 
electric current, and ultrasound, have been explored to disrupt SC layer to facilitate transdermal 
drug delivery [2,3,5-9]. Despite years of research and development, little success has been 
achieved in this field either due to low efficient SC ablation or induction of skin irritation or other 
adverse reactions [2,3].  
 
Lasers have been explored to facilitate transdermal drug delivery [10,11], but face similar 
challenges as mentioned above. In this regard, a low-fluence laser induces quick skin recovery, 
but it is unable to efficiently ablate SC layer [10,12]. On the other hand, a high-fluence laser can 
efficiently ablate SC layer, but has a high risk of skin damage and infection [10,12,13]. This 
dilemma is efficiently addressed by the advent of an ablative fractional laser (AFL) technology. 
AFL is based on Fractional Photothermolysis [14], an innovative concept in skin resurfacing 
field. Instead of illuminating big laser beams with a few millimeters in diameter for full-surface 
SC ablation, AFL emits an array of focused laser beams with ten to hundred micrometers in 
diameter to vaporize tiny skin tissues and generate microchannels (MCs) in the skin surface 
[12,15,16]. These MCs can span from skin surface to deep epidermal or dermal tissue, 
depending on laser conditions. The micro-fractional laser ablation spares the majority of the skin 
and causes minimal skin reactions, leading to complete and fast skin recovery in 2~3 days 
[12,15,16]. The efficient SC ablation and quick skin recovery make AFL an attractive technology 
for transdermal drug delivery. 
 
In the last decade, AFL has been found to efficiently enhance transdermal delivery of a variety 
of hydrophilic molecules, including small chemicals, macromolecules, and nanoparticles [12,15-
17]. Different dosage forms, like liquids, gels, lotions, and creams, show good delivery across 
AFL-treated skin [12,15-17]. In pursuit of a more convenient and controlled delivery platform, we 
explored powder drug delivery through AFL-generated skin MCs [18,19]. In that study powder 
drugs were coated onto adhesive patch surface in the same pattern as AFL-generated skin MCs 
[18,19]. Powder drug-coated array patches were then topically applied onto AFL-generated skin 
MCs to deliver drugs into the skin via these MCs [18,19]. We found the micro-fractional 
epidermal powder delivery (EPD) is capable of delivering both small chemicals and 
macromolecules into the skin with >80% drug doses delivered within 1 hour [19]. However, due 
to the limited surface coating, the amount of drugs that can be delivered per patch is rather low 
and may not be practical for high-dose drug delivery in humans. To increase the delivery 
capacity, this study explores the coating of powder drugs into high-aspect-ratio, micro-coating 
channels (MCCs) and then investigates drug delivery efficiency, pharmacokinetics, and 
bioavailability in preclinical animal models. We found the volumetric coating significantly 
improved drug coating capacity and prolonged drug release to ~12 hours. Small chemicals can 
be directly coated for high efficient delivery, while sugar excipients are required to induce high 
efficient delivery for biologics. Remarkably, the sustained epidermal powder delivery (sEPD) 
was found to significantly improve drug bioavailability and functionality in vivo when compared 
to oral or injection delivery.  
 
 
Materials and Methods 
Reagents 
Sulforhodamine B (SRB, 230161), ovalbumin (OVA, A5503), zidovudine (AZT, A2169), mannitol 
(M4125), sucrose (S9378), trehalose (T5251) were purchased from Sigma (St. Louis, MO). AZT 
internal standard 3’-Azido-3’-deoxythymidine (AZT-IS, MG103) was purchased from Moravek 
Biochemicals (Brea, CA). Anti-mouse programmed death (PD)-1 (CD279) antibody (clone 
RMP1-14) and rat IgG2a isotope control were obtained from Bio X Cell (West Lebanon, NH).  
 
Animals 
BALB/c and C57BL/6 mice (male, 6-8 weeks old) were purchased from Charles River 
Laboratories (Wilmington, MA). Animals were housed in animal facilities of University of Rhode 
Island (URI) and anesthetized for hair removal, laser treatment, and patch application. All 
animal procedures were approved by Institutional Animal Care and Use Committees of URI. 
 
Laser device 
An UltraPulse Fractional CO2 Laser (Lumenis Inc.) was used in this study to generate patch 
MCCs and skin MCs. 
 
Patch preparation, coating, and extraction 
A 750μm-thick polycarbonate patch laminated with an adhesive layer was exposed to 5 pulses 
of AFL laser at 40mJ energy and 5% coverage to generate 9×9 array of MCCs in 6×6 mm2 area. 
Drug powder was repeatedly pushed into these MCCs with a spatula until full. Powder-coated 
9×9 array patches were directly applied or cut into four 4×4 array patches and then applied onto 
AFL-treated skin. Powder array patches were immersed into phosphate buffer saline (PBS) with 
agitation to extract coated or remaining drugs. 
 
Patch application 
Dorsal mouse skin was exposed to AFL at 5mJ energy and 5% coverage to generate 4×4 MCs 
in 2×2 mm2 skin area unless otherwise specified. Powder array patches were then topically 
applied on the laser-treated skin with patch MCCs and skin MCs aligned. Patches were then 
firmly pressed on the skin to ensure a tight patch/skin contact. A narrow bandage was used to 
keep patches in position before removal at indicated times. 
 
Gelatin skin model 
Gelatin powder from porcine skin (60 bloom, type A, Electron Microscopy Sciences) was 
dissolved in warm water and then poured into 35mm petri dishes to form 5% gel with ~1 cm in 
thickness. 
 
In vitro Franz Cell system 
Franz Cell system with orifice diameter of 5mm and recipient chamber volume of 1.5ml were 
custom-made by PermeGear. Patch-applied skin was excised and mounted onto the surface of 
the recipient chamber. Donor chamber was laid atop and assembled with the help of a clamp. 
PBS (1.5ml) was added into the recipient chamber and bubbles were removed to ensure full 
skin contact with PBS. PBS in the recipient chamber was continuously stirred. At different times, 
100μl solution was removed from the recipient chamber for quantification of drug 
concentrations. Equal volume of fresh PBS was added back to maintain an equal volume during 
the entire study. 
 
Serum SRB quantification 
Blood was collected into heparin-containing tubes and quickly centrifuged to separate serum 
from blood cells. Fluorescence intensity of SRB was measured at 565/585nm after 1:20 dilution 
of serum samples into PBS. 
 
Oral gavage 
Oral gavage was performed following a published protocol [20]. In brief, mice were restrained 
and a sterile plastic mouse-specific feeding tube (Cadence Science, Inc.) was inserted and 
advanced into the stomach. Solutions were slowly injected and feeding tube was pulled out 
afterwards. 
 
LC-MS/MS quantification of AZT 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to quantify AZT 
levels as reported [21]. Patch extracts and AZT standards (5, 20, 50, 100, 200, 400ng/ml) were 
mixed with 100ng/ml AZT-IS. Serum samples were diluted by 20 times, mixed with 100ng/ml 
AZT-IS, filtered through 10kDa cutoff Amicon filter. Samples were loaded into an AB Sciex 4500 
QTRAP LC-MS/MS equipped with Shimadzu LC-20AD pumps and a QTRAP 4500 System. A 
Synergi Hydro-RP 80A, 2.0×150 mm, 4μm particle size analytical column (Phenomonex, 
Torrance, CA) was used for sample separation. Acquisition was performed in multiple reaction 
monitoring (MRM) mode using m/z 268/127 for AZT and 271/130 for AZT-IS detection. A 
standard curve was generated by plotting peak area ratios of AZT to AZT-IS against AZT 
concentrations and used to quantify AZT levels in unknown samples.  
 
Insulin biotinylation 
Insulin (Humalog, insulin lispro injection, Eli Lilly & Co, Indianapolis, IN) was biotinylated 
using EZ-link Sulfo-NHS-biotinylation kit (Thermo Scientific, Rockford, IL) by following 
manufacturer's instructions. Briefly, insulin (400μl) was mixed with 10mM biotin reagent (482μl) 
and then incubated at room temperature for 0.5 hour followed by dialysis against PBS to 
remove biotin reagent. Biotin-insulin concentration was determined by BCA Protein Assay 
(Pierce, Rockford, IL). To prepare insulin powder, biotin-insulin was mixed with mannitol at 1:25 
ratio (w/w) and then lyophilized. 
 
Serum insulin detection 
To detect biotin-insulin levels, ELISA plates were coated with 20µg/ml anti-insulin antibody 
(Clone: 3A6, Novus Biologicals) at 4˚C overnight. After blocking in PBS supplemented with 2% 
fetal bovine serum (FBS), diluted serum samples were added and incubated at room 
temperature for 2 hours. After washing, streptavidin-HRP conjugates (Thermo Fisher) were 
added (1:4000) and plates were kept at room temperature for 1 hour. After washing, TMB 
substrates were added and reactions were stopped by 2M H2SO4. Absorbance at 450nm was 
read in a microplate reader (Molecular Device).  
 
Diabetes model and blood glucose level (BGL) detection 
Streptozotocin (STZ, Sigma, S0130) was used to induce diabetes in mice. In brief, STZ was 
dissolved in citric acid buffer (pH4.5), filtered through a 0.22μm membrane, and i.p. injected to 
BALB/c mice (6-8 weeks) at 160mg/kg within 15 minutes of preparation. BGLs were measured 




B16F10 melanoma cells (ATCC, CRL-6475) were cultured in DMEM media supplemented with 
10% FBS, 2 mM L-glutamine, and 1% penicillin-streptomycin. Cells were harvested at ~80% 
confluent, washed in PBS, and 5×105 cells were s.c. injected to right flank back of C57BL/6 
mice. Tumor growth was monitored by a digital caliper and tumor volume was calculated by the 




Values were expressed as Mean ± SEM (standard error of mean). Student’s t-test was used to 
analyze the difference between groups. P value was calculated by PRISM software (GraphPad, 
San Diego, CA) and considered significant if it was less than 0.05. 
  
Results 
Sustained SRB delivery 
Model drug SRB was first used to explore sEPD. Five pulses of AFL at 40mJ energy and 5% 
coverage were found to generate high-aspect-ratio, cone-shaped MCCs in a 750μm-thick patch 
with each MCC ~200μm in base diameter and ~600μm in depth (upper panels, figure 1A). 
Commercial SRB powder was directly coated into these MCCs (lower panels, figure 1A). We 
found ~8μg SRB powder could be coated into each MCC, corresponding to a 16-fold increase 
as compared to fractional surface coating.[19] Next laser at 5mJ energy and 5% coverage was 
used to generate skin MCs with an average diameter of 66μm in BALB/c mice (figure 1B). 
 
 
Figure 1. Patch MCCs and skin MCs 
A. Top and side view of representative blank (upper panels) and powder SRB-coated MCCs 
(lower panels) under Nikon Eclipse E600 microscope. Scale: 200μm. B. Image of a 
representative skin MC under Nikon Eclipse E600 microscope. Scale: 40μm. C. Illustration of 
relative size of patch MCCs and skin MCs used to explore powder drug delivery in this study. 
 
Powder SRB-coated array patches were then topically applied with patch MCC/skin MC aligned 
to explore powder SRB delivery via skin MCs. The relative size of patch MCCs and skin MCs in 
this study was shown in figure 1C. We first explored powder SRB delivery in in vitro Franz Cell 
systems (figure 2A). For comparison, powder SRB-coated array patches were also topically 
applied on tape-stripped or intact skin as our previous report.[15] As shown in figure 2B, powder 
SRB showed the highest delivery efficiency across AFL-treated skin. SRB levels in recipient 
chambers quickly rose to 62.9μg/ml in AFL group 2 days after delivery, while those in tape 
stripping group reached only 21.7μg/ml (figure 2B). SRB levels in recipient chambers of AFL 
group reached 75.5μg/ml on day 7, while those in tape stripping group only reached 54.1μg/ml 
(figure 2B). No significant delivery was observed in non-treated intact skin group and SRB levels 
was only 2.5μg/ml on day 7 (figure 2B). Early-phase delivery showed the same trend with SRB 
levels significantly higher in AFL group than those in tape stripping or intact skin group (figure 
2C). Overall 85% and 60% SRB was delivered within 7 days across AFL-treated and tape-
stripped skin, respectively, while less than 3% SRB was delivered across intact skin (figure 2D). 
These data indicated that powder SRB coated into MCCs of the thick patch could be efficiently 
and sustainably delivered through AFL-generated skin MCs.  
 
 
Figure 2. Sustained powder SRB delivery in Franz cell systems 
A. Assembly of the Franz cell system. Skin of BALB/c mice was exposed to AFL at 5mJ energy 
and 5% coverage, or tape stripped, or left untreated followed by topical application of powder 
SRB-coated 4×4 array patches. Patch-applied skin was mounted onto the recipient chamber 
and then assembled with donor chamber. Recipient chamber was filled with 1.5mL PBS with 
continuous stirring for 7 days. B. Cumulative SRB concentrations in recipient chambers of 
different groups. n=4. C. Cumulative SRB levels in early-phase delivery of different groups. 
Student’s t-test was used to compare difference between AFL and tape stripping or non-treated 
control group at different time points. *, p<0.05; **, p<0.01. D. SRB delivery efficiency on day 7 
in different groups.  
 
Sustained powder SRB delivery was also explored in live BALB/c mice. Powder SRB-coated 
array patches were topically applied onto AFL-treated skin of BALB/c mice and patches were 
removed at different times. Pictures of the patches and skins were taken. Spot size of powder 
SRB coating gradually reduced on AFL-treated skin with significant reduction occurred between 
3-9 hours (upper panels, figure 3A). Spots of SRB coating completely disappeared within 15 
hours on AFL-treated skin, but remained with little change on intact skin even 24 hours later 
(upper panels, figure 3A). In parallel, pink-colored SRB emerged on AFL-treated skin right after 
patch application and remained visible in entire 24 hours (lower panels, figure 3A). SRB color in 
AFL-treated skin had no significant change in the first 3 hours, gradually increased after 5 hours 
and reduced after 12 hours, and remained visible at 24 hours (lower panels, figure 3A). 
Interestingly, the dark brown color of SRB, indicative of highly concentrated SRB solution, was 
evident in 11 out of 16 skin MCs between 5-9 hours, hinting significant SRB delivery during this 
period (lower panels, figure 3A). No significant pink color was found on intact skin even 24 
hours later (lower panels, figure 3A). We further quantified SRB amount in patches before and 
24 hours after delivery and found >90% SRB disappeared from patches applied onto AFL-
treated skin, while >95% SRB remained on patches applied onto intact skin (figure 3B). 
Considering <0.5% SRB remained on skin surface in each group (data not shown), we 
concluded that powder SRB reached more than 90% delivery efficiency on AFL-treated skin and 
<5% delivery efficiency on intact skin (figure 3B). Serum SRB levels were detectable right after 
patch application and maintained at relatively low levels in the first 2 hours (figure 3C). Serum 
SRB levels increased and peaked between 6-8 hours and then declined to baseline after 15 
hours (figure 3C). The timeline to reach peak serum levels correlated well with the above local 
delivery data. Dose-dependent SRB delivery was also evident with higher serum SRB levels in 
four-patch group as compared to one-patch group (figure 3C). 
 
 
Figure 3. Sustained powder SRB delivery in vivo 
A. Pictures of patch (upper panels) and skin (lower panels) at different time points after topical 
application of powder SRB-coated 4×4 array patches onto AFL-treated or intact skin of BALB/c 
mice. Scale: 667μm. B. Delivery efficiency of powder SRB across laser-treated and non-treated 
control skin. n=4. C. Serum SRB levels at different times after topical application of four or one 
SRB-coated 4×4 array patches onto AFL-treated skin of BALB/c mice. n=4. 
 
Gelatin skin to explore underlying mechanisms 
To more closely observe powder delivery kinetics within MCCs, 5% gelatin gel that mimics 
toughness and elasticity of human skin was prepared and further layered with a 3M Tegaderm 
film to prevent water loss during the following studies [24]. Gelatin gel-based skin model 
(abbreviated as gelatin skin) was exposed to laser generating the same pattern of MCs followed 
by topical application of powder SRB-coated array patches as above. SRB was found to 
gradually release into AFL-treated gelatin skin. Pink colored SRB was visible right after patch 
application and then gradually expanded to surrounding areas (figure 4A). Patch MCC imaging 
revealed channel color change from initial black to dark pink at ~5 hours, then to light pink at ~9 
hours, and finally to background color at ~19 hours (figure 4B). Enlarged pictures showed clear 
signs of water infiltration at 0.5 hour, significant water infiltration at 5 hours, significant SRB 
delivery at 9 hours, and almost complete SRB delivery at 19 hours. This pattern of channel color 
change reflected active water infiltration, drug dissolution and diffusion inside MCCs, which is 
consistent with the observed in vivo delivery (figure 3A). 
 
Figure 4. Sustained powder SRB delivery in gelatin skin  
Powder SRB-coated 4×4 array patches were topically applied onto AFL-treated or intact gelatin 
skin. At different times, topical view of the delivery (A) and images of patch MCCs (B) were 
taken by a digital camera. Enlarged pictures of patch MCCs were shown in lower panels of B. 
Blue arrow points to signs of water infiltration at 0.5 hour or MCCs with clear color change at 
later time points. 
 
Sustained AZT delivery with improved bioavailability 
Next antiretroviral drug AZT (3'-azido-3'-deoxythymidine) was used to explore the sEPD in 
BALB/c mice. AZT belongs to nucleoside analog reverse-transcriptase inhibitor (NRTI) family 
and is taken twice daily orally together with other antiretroviral drugs to control human 
immunodeficiency virus (HIV) status [25]. Sustained delivery is promising to reduce dosing 
frequency and improve adherence of antiretroviral therapy. Commercial AZT powder was 
directly coated and about 7.5μg AZT powder could be coated into each MCC, similar to powder 
SRB coating. AZT powder-coated array patches were topically applied onto AFL-treated skin as 
above. Oral gavage of patch extracts served as control. As shown in figure 5A, off-white AZT 
powder almost completely disappeared from patches applied onto AFL-treated skin within 15 
hours and MCCs after delivery were indistinguishable from those in blank patches. We further 
quantified AZT amount in patches before and after delivery and found >95% AZT was delivered 
in AFL-treated skin, while <5% AZT was delivered in intact skin (figure 5B). Serum AZT levels 
were detected by LC-MS/MS and peak area ratios were used to calculate serum AZT levels 
based on the standard curve (figure 5C). Serum AZT levels peaked at 2.7μg/ml at 30 minutes 
and declined to baseline at 3 hours in oral delivery, while serum AZT levels peaked at 1.0μg/ml 
at 4 hours and declined to baseline at ~15 hours in sEPD (figure 5D). We further calculated 
area under the concentration-to-time curve (AUC) and found AUC of oral delivery and sEPD 
was 2.8 and 5.5μgꞏhr/ml, respectively. The ~2-fold increase of AUC indicated improved 
bioavailability with sEPD. Considering water evaporation might play a crucial role in sEPD, laser 
parameters were modified. As shown in figure 5E, reduction of laser energy from 5 to 2.5mJ 
significantly reduced water evaporation measured by transepidermal water loss (TEWL) using 
Tewameter TM300 (Courage-Khazaka, Köln, Germany), while increase of laser pulses from 1 to 
2 pulses significantly increased water evaporation. We found water evaporation was positively 
correlated with early-phase drug release. As shown in figure 5F, 2 pulses of AFL at 5mJ 
induced the quickest AZT release followed by 1 pulse of AFL at 5mJ and then 1 pulse of AFL at 
2.5mJ (1 pulse was omitted hereafter for simplicity). Serum AZT levels in 5mJ/2pulse group 
peaked at a comparable level at 4 hours and then declined at a similar rate to that of 5mJ group 
(figure 5F). Serum AZT levels in 2.5mJ group peaked at 0.7μg/ml at 4 hours, which was 
significantly lower than that in 5mJ groups (figure 5F). Serum AZT levels in 2.5mJ group also 
declined with a slower rate than 5mJ groups and were still detectable at 15 hours (figure 5F). 
 
Figure 5. Sustained AZT delivery 
A. Pictures of powder AZT-coated patches before (left) and 24 hours after delivery (middle) and 
also picture of blank patches (right). Scale: 667μm. B. Delivery efficiency of powder AZT-coated 
patches on AFL-treated or non-treated control skin at 24 hours. n=4. C. Standard curve used to 
quantify serum AZT levels. AZT levels were measured by LC-MS/MS method. Peak area ratios 
of AZT to AZT-IS of standard samples were plotted against AZT concentrations. D. Serum AZT 
levels in sEPD and oral gavage delivery. n=5-9. E. TEWL value of different AFL-treated skin of 
BALB/c mice. Student’s t-test was used to compare TEWL values between groups. n=3-5. F. 
Serum AZT levels at different times after topical application of powder AZT-coated array 
patches onto different AFL-treated skin of BALB/c mice. n=6-9. 
 
 
Sustained OVA delivery in the presence of sugar excipients 
Besides small chemicals, we also explored sEPD for biologics delivery. Model macromolecule 
OVA was explored first. Lyophilized OVA was similarly coated and topically applied onto laser-
treated skin of BALB/c mice. Patches were removed 24 hours later and we found a significant 
amount of OVA powder remained inside MCCs of the thick patch (No excipient, figure 6A). The 
inefficient OVA delivery could be due to the formation of high viscosity of hydrogels and low 
diffusion capacity of macromolecules in hydrogels. Considering small sugar excipients, like 
mannitol, sucrose, trehalose, are less likely to form hydrogels due to their high water solubility 
and diffusion capacity, we explored whether incorporation of these excipients could increase 
powder OVA delivery. To this end, mannitol, sucrose, and trehalose were mixed with OVA at 
25:1 weight ratio, lyophilized, coated and delivered as above. As shown in figure 6A, inclusion of 
mannitol, sucrose, or trehalose significantly increased OVA delivery as evidenced by the 
disappearance of the majority of OVA powder from MCCs within 24 hours. Due to the relatively 
non-hygroscopic feature of mannitol as compared to sucrose and trehalose [26], mannitol was 
selected to assist the delivery of other biologics in the following studies.  
 
 
Figure 6. Increased powder OVA delivery in the presence of small sugar excipients 
Powder OVA-coated array patches in the presence or absence of mannitol, sucrose, or 
trehalose at a 1:25 mass ratio were topically applied onto AFL-generated skin MCs. Patches 
were removed 24 hours later and patch pictures before and after delivery were taken. 
Experiments were repeated 3 times and representative patch pictures were shown. Scale: 
667μm. 
 
Sustained insulin delivery with improved BGL control 
Biologics drug insulin (Humalog) was then used to explore pharmacokinetics and bioavailability 
of sEPD. Currently most of the type I diabetes patients require multiple insulin injections per day 
to control their BGLs [27,28]. Transdermal delivery eliminates needle injection and associated 
pain and is highly attractive for alternative insulin therapy. In this study, Humalog was 
conjugated to biotin to allow us to develop an ELISA assay to specifically detect human insulin 
in mouse serum (see Methods). We found biotin conjugation didn’t significantly affect blood 
glucose reduction of human insulin in STZ-induced diabetic mice (data not shown). Biotin-insulin 
(abbreviated as insulin) was mixed with mannitol, lyophilized, and coated as above. Powder 
insulin-coated array patches were topically applied onto AFL-treated skin of BALB/c mice. We 
found insulin powder completely disappeared from patches applied onto AFL-treated skin within 
24 hours and MCCs after delivery were indistinguishable from those of blank patches (figure 
7A). We further compared kinetics and bioactivity of insulin after sEPD and subcutaneous (s.c.) 
delivery in STZ-induced diabetic mice. As shown in figure 7B, serum insulin levels peaked 
369ng/ml at ~1 hour in s.c. delivery and then declined to baseline at 4 hours. Insulin delivery 
was initiated right after patch application in sEPD and serum insulin levels were maintained 
between 40-100ng/ml from 0.5 to 8 hours (figure 7B). AUC was slightly increased in sEPD as 
compared to s.c. delivery (676 vs. 580ngꞏhr/ml). Remarkably, sEPD maintained a normal BGL 
(100-130mg/dl) for at least 6 hours despite a slower rate of BGL reduction at the beginning of 
the delivery (figure 7C). In contrast, BGLs in s.c. group quickly rose after reaching the normal 




Figure 7. Sustained insulin delivery  
A. Pictures of patches before (left) and 24 hours after powder insulin delivery (middle) as well as 
picture of blank patches (right). Experiments were repeated 3 times and representative pictures 
were shown. Scale: 667μm. B-C. Powder insulin-coated patches were topically applied onto 
AFL-treated skin of STZ-induced diabetic mice or extracted for s.c. injection. At different time 
points, serum insulin levels (B) and BGLs (C) were measured. Non-treated mice served as 
control. n=7-9.  
 
Improved anti-tumor immunotherapy of anti-PD-1 antibody  
PD-1 is mainly expressed on activated T cell surface and is an important immune checkpoint 
with the major function to suppress immune responses [29]. Antibodies against PD-1 have been 
developed and two of these antibodies (Nivolumab, Pembrolizumab) were recently approved by 
FDA to treat metastatic melanoma, non-small cell lung cancer, and also other types of tumor at 
advanced stages [30-32]. A recent report indicated sustained local release of anti-PD-1 could 
significantly enhance anti-tumor immunotherapy [33]. Here we compared sEPD with systemic 
delivery of relatively low doses of anti-PD-1 antibody (0.72mg/kg) in immunotherapy against 
murine B16F10 melanoma. Mouse-origin anti-PD-1 antibodies were dialyzed, mixed with 
mannitol, lyophilized, and coated as in insulin delivery. Intraperitoneal (i.p.) injection of anti-PD-1 
antibody, isotope control, and PBS served as controls. Treatment was initiated on day 5 and 
repeated twice on day 8 and 11. As shown in figure 8A, sEPD of anti-PD-1 antibody most 
significantly inhibited tumor growth when compared to that attained by i.p. injection of anti-PD-1 
antibody or isotope control. SEPD and i.p. injection of anti-PD-1 antibody significantly reduced 
tumor size starting from day 12 and 14, respectively, while i.p. injection of isotope control 
significantly reduced tumor size from day 16 (figure 8B). No significant difference in tumor size 
was observed between i.p. injection of anti-PD-1 antibody and isotope control in entire period 
(figure 8B). Tumor size began to show significant difference between isotope control and sEPD 
(anti-PD-1) on day 14 and between i.p. (anti-PD-1) and sEPD (anti-PD-1) on day 16 (figure 8B). 
Tumor was dissected on day 16. As shown in figure 8C, tumor weight in sEPD and i.p. injection 
of anti-PD-1 antibody groups was significantly smaller than that in PBS group. No significant 
difference in tumor weight was found between PBS and isotope control group (figure 8C). 
Tumor weight was significantly smaller in sEPD (anti-PD-1) group as compared to i.p. (anti-PD-
1) group (figure 8C). This study indicated that the novel sEPD could improve therapeutic 
efficacy of anti-PD-1 antibody in murine B16F10 melanoma models. 
 
 
Figure 8. Improved efficacy of sEPD of anti-PD-1 antibody  
C57BL/6 mice were s.c. transplanted with B16F10 melanoma cells and then treated with sEPD 
of anti-PD-1 antibody, or i.p. injection of anti-PD-1 antibody or isotope control at the same 
antibody dose, or i.p. injection of PBS on day 5, 8, and 11. Patches were removed 24 hours 
later. A. Tumor size was monitored every other day from day 8. B. Days to reach significant 
difference of tumor sizes between groups and the significant levels. Two-way ANOVA and 
Bonferroni post-test were used to compare tumor sizes between groups. C-D. Mice were 
euthanized on day 16. Tumor was dissected and tumor images were shown in C (scale: 1 cm) 
and tumor weight was shown in D. Student’s t-test was used to compare tumor weight 
difference between groups. *, p<0.05; **, p<0.01; ***, p<0.001. n=5. 
Discussion 
This study explores a novel AFL-based transdermal delivery technology, called sEPD, for 
efficient and sustained delivery of powder hydrophilic drugs across the skin. SEPD is based on 
coating powder drugs into MCCs of a thick patch followed by topical application of powder drug-
coated array patches onto AFL-generated skin MCs to deliver drugs into the skin. AFL has been 
actively explored to facilitate transdermal drug delivery in the last decade. In these studies, 
drugs were often prepared as liquids, gels, or creams and then topically applied onto AFL-
treated skin [12,15-17]. Most of these studies focused on local drug delivery to treat skin 
diseases [12,15-17]. To our knowledge, this was the first study to explore systemic drug delivery 
in a powder form via AFL-generated skin MCs. We found water-soluble drugs SRB and AZT can 
be directly coated for high efficient delivery (figure 2-5), while biologics drugs OVA, insulin, and 
anti-PD-1 antibody require pre-mixing with small sugar excipients to induce high efficient 
delivery (figure 6-8). The low efficient biologics delivery in the absence of sugar excipients may 
be caused by formation of high viscosity of hydrogels and a low diffusion ability of 
macromolecules in hydrogels. Based on rough calculation, drug concentration will reach over 
1,000 mg/ml if 8μg drug powder is completely dissolved inside the cone-shaped MCC in figure 
1A. Although this is not the case in sEPD, this calculation indicates that drugs are most likely 
delivered at saturated conditions at early stages of delivery considering rare drugs can have 
such a high water solubility. We expect drugs with high water solubility, low molecular weight, 
and low viscosity to have efficient sEPD. Yet whether these parameters can be established as 
quantitative criteria to predict efficiency of sEPD remains to be explored. In this study we found 
disaccharides, like mannitol, sucrose, and trehalose, were effective to enhance biologics 
delivery. Other water-soluble, small-molecular-weight chemicals, like amino acids, may also be 
able to enhance biologics delivery. The optimal excipients to enhance biologics delivery and 
maintain biologics activity in sEPD need to be explored in the future. In this study we found the 
relatively high mannitol to biologics ratio (25:1) rendered biologics delivery very similar to 
chemical drug delivery (figure 3, 5, 7).  
 
SEPD induced a biphasic drug release with 3-15% drugs first released in 1-2 hours and the 
majority of the remaining drugs then released in the next 10-12 hours (figure 3C, 5D, 7B). 
Biphasic drug release is likely caused by differential powder dissolution in early and late phases. 
It was reported that interstitial fluid can quickly fill skin MCs after AFL treatment [34]. Patch 
application and firm pressing could bring lower portion of patch-coated drug powder in close 
contact with skin MC-filled interstitial fluid. The wetting and dissolution of this part of powder 
likely contribute to the early-phase drug release. The dissolution and delivery of remaining drug 
powder likely depend on continuous water evaporation from skin MCs. This pattern of in vivo 
delivery is recapitulated in powder SRB delivery in in vitro gelatin skin. We observed clear signs 
of water infiltration into lower portion of patch MCCs within 30 minutes and water infiltration into 
entire patch MCCs at 5 hours as evidenced by change of MCC color (figure 4B). In second 
phase of delivery, we observed uniform SRB color along long axis of each MCC, supporting 
relatively quick dissolution of entire remaining powder and continuous release rather than partial 
dissolution and pulsed release. SEPD takes advantage of interstitial water filled in and 
evaporated from skin MCs to gradually dissolve topical drug powder for sustained drug release. 
We found sEPD could be accelerated by increase of water evaporation and decelerated by 
reduction of water evaporation as shown in figure 5F. This finding supports generation of skin 
MCs that differ in water evaporation rate to modify drug release. Similar to traditional patches, 
daily activities, like hot baths, sunbaths, that increase skin temperature and water evaporation 
rate, should be avoided during sEPD. High-aspect-ratio MCCs are also key to induce sustained 
drug release as we found coating the same amount of powder on full patch surface induced 
much faster drug release (data not shown). Although the underlying reasons are unknown, we 
believe the overall distances that water molecules travel to dissolve the deepest drug powder in 
the coating or the lastly dissolved drug molecules travel to reach skin MCs could significantly 
impact the duration of drug release. Only one type of patch MCCs was explored for sustained 
drug release in this study. The impact of patch MCC shape and dimension on sustained drug 
release needs to be explored to better understand the potential of the novel delivery platform for 
clinical use. 
 
SEPD was found to significantly improve drug bioavailability and functionality in vivo. For 
example, sEPD increased bioavailability of AZT by ~100% as compared to oral gavage delivery 
(figure 5D); sEPD of insulin maintained blood glucose levels in normal range much longer than 
s.c. injection delivery in STZ-induced diabetic mice (figure 7C); sEPD of anti-PD-1 antibody 
more significantly inhibited B16F10 tumor growth in murine models as compared to i.p. injection 
delivery (figure 8). The improved bioavailability and functionality are expected to be caused by 
sustained release considering the same doses were delivered between sEPD and control oral 
or injection delivery. The advantages of sEPD for different types of drug delivery warrants 
further development of this technology for clinical use. In this study we only explored powder 
drug delivery via AFL-generated skin MCs. Considering other technologies, like microneedles 
and radiofrequencies, can also generate similar skin MCs [35,36], we are expecting similar 
deliveries after topical application of powder array patches on skin MCs generated by these 
technologies. Powder array patches in conjunction with these evolving skin MC-generating 
technologies will open a new avenue for safe and efficient transdermal delivery of hydrophilic 
drugs regardless of chemical structure and molecular weight. 
 
Powder array patches have relatively high coating capacity considering no excipients are 
required for chemical drug delivery and only small sugar excipients are required for biologics 
drug delivery. In addition, drug coating amount can be conveniently expanded by enlarging 
patch MCC volume. SEPD is highly attractive to biologics drug delivery due to its needle-free, 
painless delivery, and sustained drug release with potentially improved bioavailability and 
functionality. The incorporation of sugar excipients, especially those with protein stabilization 
activities, is also promising to improve biologics stability and eliminate cold-chain storage. 
Furthermore, biologics powder array patches can be sealed in a small package to reduce 
shipping and storage cost. Direct powder delivery also eliminates human errors that may occur 
during reconstitution and injection of biologics drugs. SEPD is also very attractive to hydrophilic 
chemical drug delivery by bypassing the first-pass metabolism, avoiding the degradation of 
drugs in the GI tract, and sustaining drug release over time. SEPD generates lower peak serum 
drug levels and is likely to reduce toxicity for drugs with narrow therapeutic index. SEPD with 
multi-day sustained release is likely to reduce dosing frequency and improve adherence to 
treatment. SEPD significantly expand chemical drugs that can be delivered via the skin. A 
handheld laser ablation and patch application device can also be fabricated to facilitate clinical 
translation of this technology.  
 
Conclusion 
In summary, we developed a novel transdermal delivery platform, called sEPD, for safe, 
efficient, and sustained delivery of hydrophilic drugs across the skin. SEPD takes advantage of 
slow water evaporation from skin MCs to gradually dissolve topical ‘bulk’ drug powder inside 
deep MCCs to induce sustained drug release. Both chemical and biologics drugs can be 
efficiently and sustainably delivered by sEPD. Remarkably, we found sEPD could increase AZT 
bioavailability by ~100% as compared to oral gavage delivery, maintain BGLs in normal range 
much longer than s.c. injection delivery, and significantly improve immunotherapy efficacy of 
anti-PD-1 antibody against B16F10 melanoma. The improved bioavailability and functionality in 
vivo and the advantages of direct powder delivery warrant further investigation of sEPD in 
conjunction with skin MC-generating technologies, like AFL, microneedle, and radiofrequency, 
for hydrophilic drug delivery.  
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